Crystal Oaks | |
1500 Calvary Church Road, Po Box 680, Festus, Missouri 63028 | |
(636) 933-1818 | |
Name | Crystal Oaks |
---|---|
Location | 1500 Calvary Church Road, Po Box 680, Festus, Missouri |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 131 |
Occupancy Rate | 72.06% |
Medicare ID (CCN) | 265369 |
Legal Business Name | Crystal Oaks Long Term Care |
Ownership Type | Non Profit - Corporation |
NPI Number | 1467592618 |
Organization Name | CRYSTAL OAKS LONG TERM CARE |
Doing Business As | CRYSTAL OAKS |
Address | 1500 Calvary Church Rd, Festus, MO 63028 |
Phone Number | 636-933-1818 |
News Archive
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.
BioInvent International AB and ThromboGenics NV announce today that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer.
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.
Scientists from the Universidad de Lleida (University of Lleida) have published a study confirming that maize seeds are an effective and sure platform within molecular agriculture to alleviate diseases. Over the next few years AIDS could be one of the first diseases to benefit from these results, although regulations for this technology are being developed at the same time as research is being undertaken.
› Verified 7 days ago
NPI Number | 1841909694 |
Organization Name | CRYSTAL OAKS NURSING AND REHAB LLC |
Address | 1500 Calvary Church Road, Festus, MO 63028 |
Phone Number | 636-933-1818 |
News Archive
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.
BioInvent International AB and ThromboGenics NV announce today that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer.
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.
Scientists from the Universidad de Lleida (University of Lleida) have published a study confirming that maize seeds are an effective and sure platform within molecular agriculture to alleviate diseases. Over the next few years AIDS could be one of the first diseases to benefit from these results, although regulations for this technology are being developed at the same time as research is being undertaken.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.
BioInvent International AB and ThromboGenics NV announce today that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer.
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.
Scientists from the Universidad de Lleida (University of Lleida) have published a study confirming that maize seeds are an effective and sure platform within molecular agriculture to alleviate diseases. Over the next few years AIDS could be one of the first diseases to benefit from these results, although regulations for this technology are being developed at the same time as research is being undertaken.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 8.27 | 14.46 |
Percentage of long-stay residents who lose too much weight | 4.02 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 24.82 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.26 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.89 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.29 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.94 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 14.37 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 3.94 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 9.01 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 32.75 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 3.89 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 72.63 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.48 | 82.93 |
News Archive
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.
BioInvent International AB and ThromboGenics NV announce today that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer.
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.
Scientists from the Universidad de Lleida (University of Lleida) have published a study confirming that maize seeds are an effective and sure platform within molecular agriculture to alleviate diseases. Over the next few years AIDS could be one of the first diseases to benefit from these results, although regulations for this technology are being developed at the same time as research is being undertaken.
› Verified 7 days ago
Crystal Oaks Location: 1500 Calvary Church Road, Po Box 680, Festus, Missouri 63028 Phone: (636) 933-1818 | |
Fountainbleau Nursing Center Location: 1349 Highway 61, Po Box 700, Festus, Missouri 63028 Phone: (636) 937-3500 |